| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 64 | 2024 | 5097 | 3.490 |
Why?
|
| Humans | 114 | 2025 | 14537 | 1.890 |
Why?
|
| Research Design | 4 | 2023 | 124 | 1.600 |
Why?
|
| Sex Workers | 10 | 2023 | 116 | 1.530 |
Why?
|
| Female | 75 | 2024 | 9103 | 1.490 |
Why?
|
| Male | 63 | 2024 | 6754 | 1.390 |
Why?
|
| Cross-Sectional Studies | 32 | 2024 | 1422 | 1.360 |
Why?
|
| Tuberculosis | 9 | 2023 | 543 | 1.270 |
Why?
|
| Patient Acceptance of Health Care | 7 | 2024 | 256 | 1.260 |
Why?
|
| South Africa | 61 | 2025 | 7596 | 1.260 |
Why?
|
| Adult | 49 | 2024 | 5913 | 1.180 |
Why?
|
| HIV-1 | 14 | 2022 | 1260 | 1.070 |
Why?
|
| Anti-HIV Agents | 14 | 2024 | 1324 | 1.050 |
Why?
|
| Quality of Life | 5 | 2024 | 177 | 1.000 |
Why?
|
| Adolescent | 29 | 2024 | 2985 | 0.890 |
Why?
|
| AIDS Vaccines | 5 | 2022 | 152 | 0.880 |
Why?
|
| Mycobacterium tuberculosis | 6 | 2023 | 329 | 0.860 |
Why?
|
| Sexual Behavior | 9 | 2020 | 320 | 0.820 |
Why?
|
| Young Adult | 24 | 2024 | 2498 | 0.780 |
Why?
|
| Prospective Studies | 16 | 2024 | 1160 | 0.760 |
Why?
|
| Health Status Indicators | 1 | 2020 | 17 | 0.730 |
Why?
|
| Life Expectancy | 1 | 2020 | 31 | 0.720 |
Why?
|
| Adolescent Behavior | 3 | 2015 | 60 | 0.710 |
Why?
|
| Coinfection | 4 | 2022 | 276 | 0.700 |
Why?
|
| Breast Feeding | 2 | 2020 | 120 | 0.690 |
Why?
|
| Sex Offenses | 3 | 2022 | 29 | 0.690 |
Why?
|
| Tuberculosis, Pulmonary | 5 | 2023 | 324 | 0.680 |
Why?
|
| Family | 3 | 2024 | 35 | 0.680 |
Why?
|
| Lactobacillus | 1 | 2019 | 7 | 0.670 |
Why?
|
| Probiotics | 1 | 2019 | 12 | 0.670 |
Why?
|
| AIDS-Related Opportunistic Infections | 3 | 2021 | 195 | 0.670 |
Why?
|
| Vaginosis, Bacterial | 1 | 2019 | 19 | 0.670 |
Why?
|
| Risk Factors | 13 | 2024 | 1475 | 0.660 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 71 | 0.660 |
Why?
|
| Anti-Bacterial Agents | 2 | 2019 | 293 | 0.650 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 104 | 0.640 |
Why?
|
| Exercise | 1 | 2020 | 205 | 0.600 |
Why?
|
| Violence | 4 | 2023 | 68 | 0.600 |
Why?
|
| Substance-Related Disorders | 5 | 2022 | 51 | 0.590 |
Why?
|
| Wounds and Injuries | 1 | 2017 | 26 | 0.580 |
Why?
|
| Sputum | 5 | 2023 | 135 | 0.570 |
Why?
|
| Anti-Retroviral Agents | 8 | 2024 | 551 | 0.550 |
Why?
|
| Antitubercular Agents | 3 | 2023 | 322 | 0.550 |
Why?
|
| Circumcision, Male | 5 | 2019 | 99 | 0.540 |
Why?
|
| CD4 Lymphocyte Count | 10 | 2017 | 656 | 0.540 |
Why?
|
| Noncommunicable Diseases | 4 | 2022 | 77 | 0.540 |
Why?
|
| Logistic Models | 9 | 2024 | 254 | 0.520 |
Why?
|
| HIV Seropositivity | 5 | 2022 | 265 | 0.510 |
Why?
|
| Middle Aged | 17 | 2024 | 3601 | 0.510 |
Why?
|
| HIV | 7 | 2021 | 380 | 0.500 |
Why?
|
| Infant | 17 | 2024 | 2244 | 0.480 |
Why?
|
| Child | 18 | 2024 | 2242 | 0.480 |
Why?
|
| Education, Public Health Professional | 1 | 2014 | 4 | 0.470 |
Why?
|
| Fellowships and Scholarships | 1 | 2014 | 12 | 0.470 |
Why?
|
| Education, Graduate | 1 | 2014 | 10 | 0.470 |
Why?
|
| Elasticity Imaging Techniques | 2 | 2024 | 2 | 0.450 |
Why?
|
| Research | 1 | 2014 | 65 | 0.450 |
Why?
|
| Poverty | 1 | 2015 | 152 | 0.450 |
Why?
|
| Primary Health Care | 2 | 2020 | 240 | 0.450 |
Why?
|
| Reproductive Health Services | 1 | 2015 | 66 | 0.450 |
Why?
|
| Immune Tolerance | 1 | 2013 | 22 | 0.450 |
Why?
|
| Incidence | 8 | 2024 | 685 | 0.440 |
Why?
|
| Delayed Diagnosis | 1 | 2013 | 17 | 0.440 |
Why?
|
| Depression | 4 | 2021 | 121 | 0.440 |
Why?
|
| Data Collection | 4 | 2018 | 86 | 0.430 |
Why?
|
| Fatty Liver | 2 | 2023 | 8 | 0.430 |
Why?
|
| Time-to-Treatment | 1 | 2013 | 42 | 0.430 |
Why?
|
| Treatment Outcome | 8 | 2023 | 889 | 0.410 |
Why?
|
| Infectious Disease Transmission, Vertical | 6 | 2022 | 472 | 0.410 |
Why?
|
| Urban Population | 1 | 2014 | 257 | 0.400 |
Why?
|
| Child, Preschool | 12 | 2023 | 1748 | 0.390 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2015 | 262 | 0.390 |
Why?
|
| Surveys and Questionnaires | 7 | 2024 | 563 | 0.380 |
Why?
|
| Pregnancy Complications, Infectious | 4 | 2022 | 529 | 0.380 |
Why?
|
| Intimate Partner Violence | 2 | 2023 | 55 | 0.380 |
Why?
|
| Patient Participation | 1 | 2011 | 13 | 0.380 |
Why?
|
| Forensic Medicine | 1 | 2011 | 1 | 0.380 |
Why?
|
| Crime Victims | 1 | 2011 | 5 | 0.370 |
Why?
|
| Physical Examination | 1 | 2011 | 10 | 0.370 |
Why?
|
| Sex Factors | 6 | 2021 | 227 | 0.370 |
Why?
|
| Socioeconomic Factors | 5 | 2015 | 411 | 0.370 |
Why?
|
| Prevalence | 11 | 2022 | 1192 | 0.360 |
Why?
|
| Cohort Studies | 7 | 2024 | 967 | 0.360 |
Why?
|
| Diabetes Mellitus | 2 | 2023 | 146 | 0.360 |
Why?
|
| Rural Population | 1 | 2014 | 654 | 0.350 |
Why?
|
| Biomarkers | 4 | 2024 | 327 | 0.350 |
Why?
|
| Kenya | 7 | 2018 | 183 | 0.350 |
Why?
|
| Otitis Media, Suppurative | 3 | 2005 | 3 | 0.340 |
Why?
|
| Patient Reported Outcome Measures | 3 | 2024 | 10 | 0.340 |
Why?
|
| Retrospective Studies | 9 | 2022 | 799 | 0.340 |
Why?
|
| Mental Health | 4 | 2021 | 91 | 0.330 |
Why?
|
| Sex Distribution | 2 | 2019 | 89 | 0.330 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2023 | 244 | 0.330 |
Why?
|
| AIDS Dementia Complex | 2 | 2020 | 29 | 0.320 |
Why?
|
| Measles Vaccine | 3 | 2022 | 34 | 0.320 |
Why?
|
| Cell Phone | 2 | 2020 | 34 | 0.320 |
Why?
|
| Longitudinal Studies | 4 | 2024 | 435 | 0.320 |
Why?
|
| Viral Load | 10 | 2021 | 819 | 0.320 |
Why?
|
| Pre-Exposure Prophylaxis | 2 | 2023 | 196 | 0.310 |
Why?
|
| Africa | 3 | 2020 | 376 | 0.310 |
Why?
|
| Growth Disorders | 2 | 2020 | 56 | 0.300 |
Why?
|
| Risk-Taking | 4 | 2020 | 121 | 0.300 |
Why?
|
| Foreskin | 2 | 2019 | 12 | 0.300 |
Why?
|
| Counseling | 2 | 2020 | 143 | 0.300 |
Why?
|
| Diagnostic Services | 1 | 2007 | 3 | 0.300 |
Why?
|
| Voluntary Programs | 1 | 2007 | 5 | 0.300 |
Why?
|
| Pregnancy | 10 | 2023 | 1862 | 0.290 |
Why?
|
| Malaria | 2 | 2020 | 213 | 0.280 |
Why?
|
| Delivery of Health Care | 2 | 2020 | 239 | 0.280 |
Why?
|
| Condoms | 3 | 2018 | 88 | 0.280 |
Why?
|
| Physicians | 2 | 2020 | 31 | 0.270 |
Why?
|
| Ambulatory Care Facilities | 4 | 2020 | 125 | 0.270 |
Why?
|
| Measles | 3 | 2022 | 36 | 0.270 |
Why?
|
| Algorithms | 2 | 2024 | 106 | 0.270 |
Why?
|
| Caregivers | 2 | 2024 | 76 | 0.250 |
Why?
|
| Drug Approval | 1 | 2025 | 3 | 0.250 |
Why?
|
| Drug Industry | 1 | 2025 | 5 | 0.250 |
Why?
|
| Pandemics | 3 | 2023 | 296 | 0.240 |
Why?
|
| Bacterial Load | 2 | 2023 | 32 | 0.240 |
Why?
|
| Drug Resistance, Viral | 2 | 2017 | 278 | 0.230 |
Why?
|
| Dementia | 1 | 2024 | 22 | 0.230 |
Why?
|
| Heterosexuality | 3 | 2021 | 30 | 0.230 |
Why?
|
| Antibodies, Viral | 2 | 2019 | 284 | 0.230 |
Why?
|
| Mass Screening | 4 | 2020 | 245 | 0.230 |
Why?
|
| Anemia, Pernicious | 1 | 2024 | 2 | 0.230 |
Why?
|
| Multiple Myeloma | 1 | 2024 | 12 | 0.230 |
Why?
|
| Parent-Child Relations | 2 | 2014 | 16 | 0.230 |
Why?
|
| Kynurenine | 2 | 2021 | 7 | 0.230 |
Why?
|
| Tryptophan | 2 | 2021 | 8 | 0.230 |
Why?
|
| Inflammation | 1 | 2024 | 104 | 0.230 |
Why?
|
| Reproductive Health | 2 | 2015 | 51 | 0.230 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2023 | 1 | 0.220 |
Why?
|
| Continuity of Patient Care | 1 | 2023 | 33 | 0.220 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2023 | 10 | 0.220 |
Why?
|
| Community-Acquired Infections | 1 | 2024 | 102 | 0.220 |
Why?
|
| Uganda | 3 | 2019 | 197 | 0.220 |
Why?
|
| Rape | 1 | 2023 | 10 | 0.210 |
Why?
|
| Data Interpretation, Statistical | 2 | 2020 | 22 | 0.210 |
Why?
|
| Pilot Projects | 2 | 2022 | 179 | 0.210 |
Why?
|
| Tobacco Use Disorder | 1 | 2022 | 7 | 0.210 |
Why?
|
| Bacillus | 1 | 2022 | 7 | 0.210 |
Why?
|
| Hyperglycemia | 1 | 2022 | 15 | 0.210 |
Why?
|
| Cannabis | 1 | 2022 | 10 | 0.210 |
Why?
|
| Writing | 1 | 2002 | 2 | 0.200 |
Why?
|
| Publishing | 1 | 2002 | 5 | 0.200 |
Why?
|
| Anemia, Iron-Deficiency | 1 | 2022 | 21 | 0.200 |
Why?
|
| Vascular Stiffness | 1 | 2023 | 41 | 0.200 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2020 | 150 | 0.200 |
Why?
|
| Anemia | 1 | 2022 | 41 | 0.200 |
Why?
|
| Guidelines as Topic | 1 | 2002 | 40 | 0.200 |
Why?
|
| Sexual Partners | 2 | 2015 | 215 | 0.200 |
Why?
|
| Dyslipidemias | 1 | 2022 | 57 | 0.200 |
Why?
|
| Insulin Resistance | 1 | 2022 | 79 | 0.200 |
Why?
|
| Physical Abuse | 1 | 2022 | 8 | 0.200 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2019 | 151 | 0.190 |
Why?
|
| Pneumococcal Vaccines | 1 | 2024 | 278 | 0.190 |
Why?
|
| Morbidity | 2 | 2019 | 37 | 0.190 |
Why?
|
| Hospitalization | 4 | 2024 | 418 | 0.190 |
Why?
|
| Papanicolaou Test | 1 | 2021 | 29 | 0.190 |
Why?
|
| Vaginal Smears | 1 | 2021 | 34 | 0.190 |
Why?
|
| Neutropenia | 1 | 2021 | 9 | 0.180 |
Why?
|
| Early Detection of Cancer | 1 | 2021 | 39 | 0.180 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2021 | 8 | 0.180 |
Why?
|
| Cell Phone Use | 1 | 2021 | 6 | 0.180 |
Why?
|
| Population Health | 1 | 2020 | 10 | 0.180 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2022 | 187 | 0.180 |
Why?
|
| Bacteriological Techniques | 1 | 2021 | 54 | 0.180 |
Why?
|
| Midwifery | 1 | 2020 | 12 | 0.180 |
Why?
|
| Movement Disorders | 1 | 2020 | 2 | 0.180 |
Why?
|
| Organizational Culture | 1 | 2020 | 7 | 0.180 |
Why?
|
| Risk Assessment | 4 | 2024 | 225 | 0.180 |
Why?
|
| Homosexuality, Male | 1 | 2021 | 52 | 0.180 |
Why?
|
| Nurses | 1 | 2020 | 32 | 0.180 |
Why?
|
| Papillomavirus Infections | 1 | 2021 | 74 | 0.180 |
Why?
|
| Betacoronavirus | 1 | 2020 | 52 | 0.180 |
Why?
|
| Mucous Membrane | 2 | 2023 | 12 | 0.180 |
Why?
|
| Developmental Disabilities | 1 | 2020 | 22 | 0.180 |
Why?
|
| Brain | 1 | 2020 | 53 | 0.170 |
Why?
|
| Reminder Systems | 1 | 2020 | 8 | 0.170 |
Why?
|
| Age Factors | 3 | 2019 | 370 | 0.170 |
Why?
|
| Immunologic Memory | 1 | 2020 | 15 | 0.170 |
Why?
|
| Haemophilus influenzae type b | 1 | 2020 | 17 | 0.170 |
Why?
|
| Patient Satisfaction | 1 | 2020 | 43 | 0.170 |
Why?
|
| Chemoprevention | 1 | 2020 | 33 | 0.170 |
Why?
|
| Antiretroviral Therapy, Highly Active | 4 | 2017 | 472 | 0.170 |
Why?
|
| Antimalarials | 1 | 2020 | 33 | 0.170 |
Why?
|
| Langerhans Cells | 1 | 2019 | 3 | 0.170 |
Why?
|
| Chemokine CCL27 | 1 | 2019 | 3 | 0.170 |
Why?
|
| National Health Programs | 1 | 2020 | 78 | 0.170 |
Why?
|
| Cefixime | 1 | 2019 | 2 | 0.170 |
Why?
|
| Doxycycline | 1 | 2019 | 3 | 0.170 |
Why?
|
| Metronidazole | 1 | 2019 | 4 | 0.170 |
Why?
|
| Polysaccharides | 1 | 2020 | 45 | 0.170 |
Why?
|
| Infant, Newborn | 6 | 2024 | 1479 | 0.170 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2021 | 115 | 0.170 |
Why?
|
| Mental Disorders | 1 | 2020 | 44 | 0.170 |
Why?
|
| Measles virus | 1 | 2019 | 6 | 0.170 |
Why?
|
| Cardiovascular Diseases | 1 | 2023 | 237 | 0.170 |
Why?
|
| Mentors | 1 | 2019 | 16 | 0.170 |
Why?
|
| Pharmaceutical Preparations | 1 | 2019 | 44 | 0.160 |
Why?
|
| Self Care | 1 | 2019 | 14 | 0.160 |
Why?
|
| Mother-Child Relations | 1 | 2019 | 20 | 0.160 |
Why?
|
| Serologic Tests | 1 | 2019 | 26 | 0.160 |
Why?
|
| Multivariate Analysis | 3 | 2014 | 171 | 0.160 |
Why?
|
| Bacterial Infections | 1 | 2019 | 54 | 0.160 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2014 | 106 | 0.160 |
Why?
|
| Health Services Needs and Demand | 2 | 2011 | 57 | 0.160 |
Why?
|
| Vagina | 1 | 2019 | 91 | 0.160 |
Why?
|
| Follow-Up Studies | 5 | 2021 | 370 | 0.160 |
Why?
|
| World Health Organization | 3 | 2025 | 137 | 0.160 |
Why?
|
| Vaccines, Conjugate | 1 | 2020 | 171 | 0.160 |
Why?
|
| Withholding Treatment | 1 | 2019 | 26 | 0.160 |
Why?
|
| gag Gene Products, Human Immunodeficiency Virus | 2 | 2019 | 20 | 0.160 |
Why?
|
| Contraceptive Agents | 1 | 2018 | 27 | 0.160 |
Why?
|
| Aged | 4 | 2024 | 1740 | 0.150 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2018 | 12 | 0.150 |
Why?
|
| Contraception Behavior | 1 | 2018 | 54 | 0.150 |
Why?
|
| Child Mortality | 1 | 2018 | 96 | 0.150 |
Why?
|
| Contraception | 1 | 2018 | 90 | 0.150 |
Why?
|
| Mothers | 1 | 2019 | 195 | 0.150 |
Why?
|
| Clinical Trials as Topic | 2 | 2023 | 112 | 0.140 |
Why?
|
| Safe Sex | 2 | 2018 | 68 | 0.140 |
Why?
|
| Dideoxynucleosides | 1 | 2017 | 29 | 0.140 |
Why?
|
| Cost of Illness | 3 | 2024 | 167 | 0.140 |
Why?
|
| Pleural Cavity | 1 | 2017 | 7 | 0.140 |
Why?
|
| Body Mass Index | 2 | 2019 | 321 | 0.140 |
Why?
|
| Wasting Syndrome | 1 | 2017 | 1 | 0.140 |
Why?
|
| Streptococcus pneumoniae | 1 | 2020 | 336 | 0.140 |
Why?
|
| Child Development | 1 | 2018 | 93 | 0.140 |
Why?
|
| Heart Defects, Congenital | 1 | 2017 | 12 | 0.140 |
Why?
|
| HIV Antibodies | 2 | 2019 | 247 | 0.140 |
Why?
|
| Predictive Value of Tests | 2 | 2017 | 188 | 0.140 |
Why?
|
| Thinness | 1 | 2017 | 18 | 0.140 |
Why?
|
| Radiography | 1 | 2017 | 80 | 0.140 |
Why?
|
| Stavudine | 1 | 2017 | 78 | 0.140 |
Why?
|
| Case-Control Studies | 3 | 2024 | 480 | 0.140 |
Why?
|
| Genital Diseases, Male | 1 | 2016 | 8 | 0.130 |
Why?
|
| Penis | 1 | 2016 | 8 | 0.130 |
Why?
|
| Malnutrition | 1 | 2017 | 56 | 0.130 |
Why?
|
| Proportional Hazards Models | 2 | 2014 | 163 | 0.130 |
Why?
|
| Self Report | 3 | 2022 | 114 | 0.130 |
Why?
|
| Alcohol Drinking | 1 | 2016 | 55 | 0.130 |
Why?
|
| Time Factors | 2 | 2015 | 507 | 0.130 |
Why?
|
| Ciprofloxacin | 2 | 2005 | 11 | 0.120 |
Why?
|
| HIV-2 | 1 | 2015 | 15 | 0.120 |
Why?
|
| HIV Seronegativity | 1 | 2015 | 52 | 0.120 |
Why?
|
| Sex Education | 1 | 2015 | 17 | 0.120 |
Why?
|
| Adolescent Health Services | 1 | 2015 | 17 | 0.120 |
Why?
|
| Directive Counseling | 1 | 2015 | 15 | 0.120 |
Why?
|
| Genitalia | 1 | 2014 | 8 | 0.120 |
Why?
|
| Comorbidity | 3 | 2022 | 188 | 0.120 |
Why?
|
| Interinstitutional Relations | 1 | 2014 | 7 | 0.120 |
Why?
|
| Cooperative Behavior | 1 | 2014 | 17 | 0.120 |
Why?
|
| Health Personnel | 3 | 2022 | 231 | 0.120 |
Why?
|
| HIV Protease Inhibitors | 1 | 2015 | 92 | 0.120 |
Why?
|
| nef Gene Products, Human Immunodeficiency Virus | 1 | 2014 | 6 | 0.120 |
Why?
|
| United Kingdom | 2 | 2024 | 33 | 0.120 |
Why?
|
| pol Gene Products, Human Immunodeficiency Virus | 1 | 2014 | 29 | 0.120 |
Why?
|
| Specimen Handling | 1 | 2014 | 105 | 0.110 |
Why?
|
| Wales | 2 | 2024 | 3 | 0.110 |
Why?
|
| Mutation | 1 | 2015 | 306 | 0.110 |
Why?
|
| Risk | 1 | 2013 | 87 | 0.110 |
Why?
|
| Communication | 1 | 2014 | 57 | 0.110 |
Why?
|
| Liver | 2 | 2024 | 74 | 0.110 |
Why?
|
| Machine Learning | 2 | 2024 | 22 | 0.110 |
Why?
|
| Prognosis | 1 | 2014 | 199 | 0.110 |
Why?
|
| Odds Ratio | 1 | 2013 | 133 | 0.110 |
Why?
|
| Floxacillin | 1 | 2013 | 6 | 0.110 |
Why?
|
| Surgical Wound Infection | 1 | 2013 | 13 | 0.110 |
Why?
|
| Triglycerides | 2 | 2023 | 47 | 0.100 |
Why?
|
| Cause of Death | 1 | 2014 | 221 | 0.100 |
Why?
|
| Communicable Disease Control | 2 | 2023 | 101 | 0.100 |
Why?
|
| Life Change Events | 1 | 2011 | 9 | 0.100 |
Why?
|
| Self Efficacy | 1 | 2011 | 11 | 0.100 |
Why?
|
| Immunoglobulin G | 1 | 2013 | 231 | 0.090 |
Why?
|
| Police | 1 | 2011 | 4 | 0.090 |
Why?
|
| Clinical Competence | 1 | 2011 | 13 | 0.090 |
Why?
|
| Sex Work | 2 | 2021 | 39 | 0.090 |
Why?
|
| Reproducibility of Results | 2 | 2020 | 217 | 0.090 |
Why?
|
| Immunization Programs | 2 | 2022 | 81 | 0.090 |
Why?
|
| Health Services Accessibility | 1 | 2013 | 280 | 0.090 |
Why?
|
| Diagnostic Tests, Routine | 2 | 2021 | 59 | 0.090 |
Why?
|
| Disease Progression | 3 | 2017 | 154 | 0.090 |
Why?
|
| Interviews as Topic | 1 | 2011 | 203 | 0.090 |
Why?
|
| Qualitative Research | 2 | 2023 | 321 | 0.080 |
Why?
|
| Health Policy | 1 | 2011 | 140 | 0.080 |
Why?
|
| Vaccination | 2 | 2022 | 365 | 0.080 |
Why?
|
| DNA, Viral | 2 | 2021 | 165 | 0.080 |
Why?
|
| Boric Acids | 2 | 2005 | 2 | 0.080 |
Why?
|
| Feasibility Studies | 2 | 2019 | 101 | 0.080 |
Why?
|
| Health Planning | 1 | 2007 | 13 | 0.070 |
Why?
|
| Sensitivity and Specificity | 2 | 2020 | 385 | 0.070 |
Why?
|
| Chronic Disease | 3 | 2020 | 107 | 0.070 |
Why?
|
| Primary Prevention | 1 | 2007 | 27 | 0.070 |
Why?
|
| RNA, Viral | 2 | 2019 | 303 | 0.070 |
Why?
|
| Patient Education as Topic | 1 | 2007 | 48 | 0.070 |
Why?
|
| Genotype | 2 | 2019 | 442 | 0.070 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2005 | 16 | 0.060 |
Why?
|
| Hypertension | 2 | 2019 | 419 | 0.060 |
Why?
|
| Anti-Infective Agents | 1 | 2005 | 57 | 0.060 |
Why?
|
| Proteomics | 1 | 2024 | 15 | 0.060 |
Why?
|
| Interleukin-6 | 1 | 2024 | 51 | 0.060 |
Why?
|
| Hematologic Diseases | 1 | 2024 | 4 | 0.060 |
Why?
|
| Liver Cirrhosis | 1 | 2024 | 28 | 0.060 |
Why?
|
| Pneumonia, Pneumococcal | 1 | 2024 | 100 | 0.060 |
Why?
|
| Lung Volume Measurements | 1 | 2023 | 1 | 0.060 |
Why?
|
| Vital Capacity | 1 | 2023 | 6 | 0.060 |
Why?
|
| Forced Expiratory Volume | 1 | 2023 | 9 | 0.060 |
Why?
|
| Spirometry | 1 | 2023 | 12 | 0.060 |
Why?
|
| Ibuprofen | 1 | 2023 | 3 | 0.050 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2023 | 10 | 0.050 |
Why?
|
| Multicenter Studies as Topic | 1 | 2023 | 22 | 0.050 |
Why?
|
| Aspirin | 1 | 2023 | 15 | 0.050 |
Why?
|
| Data Accuracy | 1 | 2023 | 9 | 0.050 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2023 | 39 | 0.050 |
Why?
|
| Aged, 80 and over | 1 | 2024 | 468 | 0.050 |
Why?
|
| Lung | 1 | 2023 | 70 | 0.050 |
Why?
|
| Firmicutes | 1 | 2022 | 7 | 0.050 |
Why?
|
| Medication Adherence | 1 | 2024 | 151 | 0.050 |
Why?
|
| Pain | 2 | 2018 | 41 | 0.050 |
Why?
|
| Health Facilities | 1 | 2023 | 40 | 0.050 |
Why?
|
| Receptors, Transferrin | 1 | 2022 | 6 | 0.050 |
Why?
|
| Bone Marrow | 1 | 2022 | 19 | 0.050 |
Why?
|
| Tobacco Smoking | 1 | 2022 | 15 | 0.050 |
Why?
|
| Ferritins | 1 | 2022 | 23 | 0.050 |
Why?
|
| Disease Eradication | 1 | 2022 | 11 | 0.050 |
Why?
|
| Iron | 1 | 2022 | 32 | 0.050 |
Why?
|
| Pulse Wave Analysis | 1 | 2023 | 61 | 0.050 |
Why?
|
| Bias | 1 | 2002 | 15 | 0.050 |
Why?
|
| Periodicals as Topic | 1 | 2002 | 8 | 0.050 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2023 | 85 | 0.050 |
Why?
|
| Cognition | 1 | 2023 | 75 | 0.050 |
Why?
|
| Blood Glucose | 1 | 2022 | 107 | 0.050 |
Why?
|
| Weight Gain | 1 | 2023 | 77 | 0.050 |
Why?
|
| Bayes Theorem | 1 | 2022 | 81 | 0.050 |
Why?
|
| Social Stigma | 1 | 2023 | 80 | 0.050 |
Why?
|
| Disease Outbreaks | 1 | 2022 | 111 | 0.050 |
Why?
|
| Autoantibodies | 1 | 2022 | 49 | 0.050 |
Why?
|
| Virus Latency | 1 | 2021 | 5 | 0.050 |
Why?
|
| HLA Antigens | 1 | 2022 | 50 | 0.050 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2021 | 60 | 0.050 |
Why?
|
| Culture Media, Conditioned | 1 | 2021 | 4 | 0.050 |
Why?
|
| Microscopy | 1 | 2021 | 21 | 0.050 |
Why?
|
| Cost-Benefit Analysis | 1 | 2023 | 253 | 0.050 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2021 | 35 | 0.050 |
Why?
|
| Pregnant Women | 1 | 2021 | 89 | 0.050 |
Why?
|
| Antibodies, Neutralizing | 1 | 2023 | 303 | 0.050 |
Why?
|
| Employment | 1 | 2021 | 27 | 0.050 |
Why?
|
| Work | 1 | 2020 | 9 | 0.050 |
Why?
|
| Sexual and Gender Minorities | 1 | 2021 | 29 | 0.050 |
Why?
|
| Research Personnel | 1 | 2020 | 19 | 0.040 |
Why?
|
| Health Care Reform | 1 | 2020 | 20 | 0.040 |
Why?
|
| Models, Biological | 1 | 2021 | 77 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 2021 | 127 | 0.040 |
Why?
|
| Students | 1 | 2020 | 50 | 0.040 |
Why?
|
| Latent Tuberculosis | 1 | 2020 | 45 | 0.040 |
Why?
|
| Africa South of the Sahara | 1 | 2021 | 353 | 0.040 |
Why?
|
| Text Messaging | 1 | 2020 | 25 | 0.040 |
Why?
|
| Cell Movement | 1 | 2019 | 13 | 0.040 |
Why?
|
| Inpatients | 1 | 2019 | 30 | 0.040 |
Why?
|
| Gene Expression Regulation | 1 | 2019 | 40 | 0.040 |
Why?
|
| Age Distribution | 1 | 2019 | 107 | 0.040 |
Why?
|
| Government Programs | 1 | 2019 | 30 | 0.040 |
Why?
|
| Public Health Surveillance | 1 | 2019 | 52 | 0.040 |
Why?
|
| Seroepidemiologic Studies | 1 | 2019 | 109 | 0.040 |
Why?
|
| Public Sector | 1 | 2020 | 82 | 0.040 |
Why?
|
| Receptors, KIR3DL1 | 1 | 2019 | 5 | 0.040 |
Why?
|
| Malaria, Falciparum | 1 | 2019 | 39 | 0.040 |
Why?
|
| Phosphoproteins | 1 | 2019 | 10 | 0.040 |
Why?
|
| Plasmodium falciparum | 1 | 2019 | 64 | 0.040 |
Why?
|
| Immunity, Cellular | 1 | 2019 | 25 | 0.040 |
Why?
|
| Immunophenotyping | 1 | 2019 | 24 | 0.040 |
Why?
|
| Focus Groups | 1 | 2020 | 196 | 0.040 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2019 | 48 | 0.040 |
Why?
|
| Receptors, KIR | 1 | 2019 | 23 | 0.040 |
Why?
|
| Marriage | 1 | 2018 | 5 | 0.040 |
Why?
|
| Overweight | 1 | 2019 | 87 | 0.040 |
Why?
|
| Antibodies, Bacterial | 1 | 2020 | 153 | 0.040 |
Why?
|
| Health Surveys | 1 | 2018 | 59 | 0.040 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2019 | 103 | 0.040 |
Why?
|
| Receptors, CCR5 | 1 | 2019 | 54 | 0.040 |
Why?
|
| Zimbabwe | 1 | 2018 | 120 | 0.040 |
Why?
|
| Patient Outcome Assessment | 1 | 2018 | 8 | 0.040 |
Why?
|
| Analgesia | 1 | 2018 | 8 | 0.040 |
Why?
|
| Pain Management | 1 | 2018 | 12 | 0.040 |
Why?
|
| Rifampin | 1 | 2019 | 197 | 0.040 |
Why?
|
| Cytokines | 1 | 2019 | 107 | 0.040 |
Why?
|
| Motor Activity | 1 | 2018 | 46 | 0.040 |
Why?
|
| Remission, Spontaneous | 1 | 2017 | 2 | 0.040 |
Why?
|
| Family Characteristics | 1 | 2018 | 135 | 0.040 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2019 | 139 | 0.040 |
Why?
|
| Viremia | 1 | 2017 | 66 | 0.040 |
Why?
|
| Drug Combinations | 1 | 2017 | 42 | 0.040 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2017 | 118 | 0.040 |
Why?
|
| Poisson Distribution | 1 | 2017 | 18 | 0.030 |
Why?
|
| Phylogeny | 1 | 2017 | 231 | 0.030 |
Why?
|
| Lamivudine | 1 | 2017 | 89 | 0.030 |
Why?
|
| Lopinavir | 1 | 2017 | 137 | 0.030 |
Why?
|
| Ritonavir | 1 | 2017 | 137 | 0.030 |
Why?
|
| Antibiotics, Antitubercular | 1 | 2017 | 47 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2017 | 133 | 0.030 |
Why?
|
| Tertiary Care Centers | 1 | 2017 | 80 | 0.030 |
Why?
|
| Psychology | 1 | 2016 | 4 | 0.030 |
Why?
|
| Obesity | 1 | 2019 | 367 | 0.030 |
Why?
|
| Social Determinants of Health | 1 | 2016 | 11 | 0.030 |
Why?
|
| Urban Health | 1 | 2016 | 78 | 0.030 |
Why?
|
| Chromatography, Affinity | 1 | 2015 | 8 | 0.030 |
Why?
|
| Hearing Disorders | 2 | 2005 | 3 | 0.030 |
Why?
|
| Evolution, Molecular | 1 | 2015 | 60 | 0.030 |
Why?
|
| Genome, Viral | 1 | 2015 | 64 | 0.030 |
Why?
|
| AIDS Serodiagnosis | 1 | 2015 | 44 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2015 | 175 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2015 | 181 | 0.030 |
Why?
|
| Enzyme-Linked Immunospot Assay | 1 | 2014 | 10 | 0.030 |
Why?
|
| Lost to Follow-Up | 1 | 2015 | 62 | 0.030 |
Why?
|
| HIV Antigens | 1 | 2014 | 26 | 0.030 |
Why?
|
| Homosexuality | 1 | 2014 | 5 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2014 | 45 | 0.030 |
Why?
|
| Adenoviridae | 1 | 2014 | 39 | 0.030 |
Why?
|
| Demography | 1 | 2014 | 105 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2013 | 156 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2013 | 127 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2013 | 279 | 0.030 |
Why?
|
| Developing Countries | 2 | 2005 | 400 | 0.020 |
Why?
|
| Maternal Age | 1 | 2010 | 22 | 0.020 |
Why?
|
| Child Welfare | 1 | 2010 | 16 | 0.020 |
Why?
|
| Auditory Threshold | 1 | 2005 | 1 | 0.020 |
Why?
|
| Tympanic Membrane | 1 | 2005 | 1 | 0.020 |
Why?
|
| Administration, Topical | 1 | 2005 | 12 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2005 | 272 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2005 | 253 | 0.010 |
Why?
|